Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : PIRS exchanges : Nasdaq save search
Soleno Therapeutics Strengthens Leadership Team with Key Appointments
Published: 2024-01-24 (Crawled : 13:00) - globenewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -3.01%
H: 0.69%
C: -0.75%
VYGR | News | $7.57 -1.05% -1.06% 310K
|
Health Technology
|
| O: 1.19%
H: 0.33%
C: -2.61%
SLNO | $39.34 -1.99% -1.97% 340K
|
Health Technology
|
| O: -1.62%
H: 1.53%
C: -2.07%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
PIRS | $11.93 -0.91% -1.35% 40K
|
Health Technology
|
| O: -3.23%
H: 4.2%
C: -1.3%
FULC | $7.28 -2.15% -2.27% 350K
|
Health Technology
|
| O: 1.04%
H: 2.28%
C: -1.33%
key therapeutics
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
Published: 2023-08-17 (Crawled : 13:00) - biospace.com/
PIRS | $11.93 -0.91% -1.35% 40K
|
Health Technology
|
| O: 5.11%
H: 10.24%
C: 2.81%
bos-342 pharmaceuticals milestone study
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
Published: 2023-07-18 (Crawled : 13:20) - biospace.com/
PIRS | $11.93 -0.91% -1.35% 40K
|
Health Technology
|
| O: 33.55%
H: 47.44%
C: -16.28%
update pharmaceuticals
Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
Published: 2023-06-21 (Crawled : 12:00) - biospace.com/
PIRS | $11.93 -0.91% -1.35% 40K
|
Health Technology
|
| O: -58.66%
H: 5.38%
C: -29.51%
prs-060 pharmaceuticals trial study
Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
Published: 2023-06-02 (Crawled : 22:00) - biospace.com/
PIRS | $11.93 -0.91% -1.35% 40K
|
Health Technology
|
| O: 0.0%
H: 5.88%
C: 5.35%
conference pharmaceuticals
Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
Published: 2023-05-22 (Crawled : 14:00) - biospace.com/
PIRS | $11.93 -0.91% -1.35% 40K
|
Health Technology
|
| O: 1.34%
H: 4.59%
C: 4.59%
prs-400 conference presentation international pharmaceuticals preclinical
OMass Therapeutics Announces Appointment of New Board Chair and Series B Extension
Published: 2023-05-15 (Crawled : 10:00) - biospace.com/
VYGR | News | $7.57 -1.05% -1.06% 310K
|
Health Technology
|
| O: -0.86%
H: 0.97%
C: 0.48%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: 0.0%
PIRS | $11.93 -0.91% -1.35% 40K
|
Health Technology
|
| O: 0.0%
H: 4.64%
C: 0.57%
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: 6.61%
H: 4.01%
C: -1.82%
FULC | $7.28 -2.15% -2.27% 350K
|
Health Technology
|
| O: 4.28%
H: 7.62%
C: 6.74%
extension therapeutics
Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
Published: 2023-05-10 (Crawled : 12:00) - biospace.com/
PIRS | $11.93 -0.91% -1.35% 40K
|
Health Technology
|
| O: -1.76%
H: 4.19%
C: 2.99%
business pharmaceuticals financial results
Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)
Published: 2023-05-04 (Crawled : 13:20) - biospace.com/
PIRS | $11.93 -0.91% -1.35% 40K
|
Health Technology
|
| O: 0.7%
H: 5.53%
C: -2.97%
prs-060 review pharmaceuticals trial
Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting
Published: 2023-04-17 (Crawled : 13:00) - biospace.com/
PIRS | $11.93 -0.91% -1.35% 40K
|
Health Technology
|
| O: 10.01%
H: 5.32%
C: 4.43%
prs-343 presentation positive pharmaceuticals meeting
Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates
Published: 2023-03-29 (Crawled : 12:20) - biospace.com/
PIRS | $11.93 -0.91% -1.35% 40K
|
Health Technology
|
| O: -25.68%
H: 17.27%
C: -3.64%
business pharmaceuticals financial results
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
Published: 2023-01-10 (Crawled : 14:00) - biospace.com/
PIRS | $11.93 -0.91% -1.35% 40K
|
Health Technology
|
| O: 4.69%
H: 5.97%
C: 5.22%
cd228 pharmaceuticals trial milestone
Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Published: 2022-11-02 (Crawled : 12:00) - biospace.com/
PIRS | $11.93 -0.91% -1.35% 40K
|
Health Technology
|
| O: 0.94%
H: 5.61%
C: -4.67%
pharmaceuticals financial update results
Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022
Published: 2022-10-26 (Crawled : 13:00) - biospace.com/
PIRS | $11.93 -0.91% -1.35% 40K
|
Health Technology
|
| O: -1.96%
H: 6.0%
C: 2.0%
pharmaceuticals update
Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS
Published: 2022-08-24 (Crawled : 13:00) - biospace.com/
PIRS | $11.93 -0.91% -1.35% 40K
|
Health Technology
|
| O: 3.33%
H: 3.23%
C: 1.94%
prs-400 preclinical presentation
Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Published: 2022-08-04 (Crawled : 12:00) - biospace.com/
PIRS | $11.93 -0.91% -1.35% 40K
|
Health Technology
|
| O: -2.2%
H: 1.12%
C: -3.37%
update results
Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022
Published: 2022-07-28 (Crawled : 12:00) - biospace.com/
PIRS | $11.93 -0.91% -1.35% 40K
|
Health Technology
|
| O: -0.55%
H: 2.21%
C: -0.55%
update
Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference
Published: 2022-06-02 (Crawled : 12:20) - biospace.com/
PIRS | $11.93 -0.91% -1.35% 40K
|
Health Technology
|
| O: -3.87%
H: 8.62%
C: 5.17%
conference
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference
Published: 2022-05-18 (Crawled : 12:20) - biospace.com/
PIRS | $11.93 -0.91% -1.35% 40K
|
Health Technology
|
| O: 3.51%
H: 2.26%
C: -1.69%
conference
Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Published: 2022-05-11 (Crawled : 12:00) - biospace.com/
PIRS | $11.93 -0.91% -1.35% 40K
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -19.73%
results
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.